caa a22 4500 467921814 CHVBK 20180406152919.0 cr unu---uuuuu 170328e20060201xx s 000 0 ger 10.1007/s10309-006-0184-2 doi (NATIONALLICENCE)springer-10.1007/s10309-006-0184-2 Wirkungen und Nebenwirkungen von Levetiracetam bei schwer behandelbaren Epilepsien [Elektronische Daten] Eine multizentrische Studie des DACH-Arbeitskreises [H. Stefan, Y. Wang-Tilz, M. Feichtinger, F. Kerling, B. Mamoli, R. Schaumann, G. Krämer] Levetiracetam in difficult to treat epilepsies Our aim was to investigate the long-term efficacy and side effect profiles of levetiracetam (LEV) in patients with difficult to treat partial and generalized epilepsies in an open labeled, multicentral study. A total of 397 patients with a seizure history from 1-80 years (average 21 years) were systematically investigated by a standardized questionnaire. Parameters concerning the seizure frequency and side effects 6 months before and 6 months during LEV treatment were investigated. The average daily dosage of LEV was 2130 mg (range 500-6000 mg). 366 patients (186 males and 180 females) aged from 4 to 88 years (average 34 y) finished the investigation. 83.2% of them had focal and 16.8% with generalized or non-localized epilepsies. The mean number of antiepileptic drugs before LEV was 4.6. The duration of LEV treatment ranged from 6 to 34 months with an average of 17.8 months. In more than 95% of cases, LEV was used as add-on therapy to carbamazepine or lamotrigine and/or valproate acid. A complete seizure control was obtained in 16.3%, a more than 75% seizure reduction was achieved in 9.5% patients and 16.9% patients had a 50% seizure reduction. The dropout rate was 9.3%, mostly (78%) because of the side effects and 22% because of the insufficient seizure control. The most common side effect was tiredness (8.8%) and followed by aggressiveness (5.7%). In a small portion of the patients (9%), seizure recurred despite increment of the dosage after the 6-month treatment. LEV is effective and safe in patients with difficult to treat epilepsies. Emotional instability is the most prominent central nervous side effect. Steinkopff-Verlag, 2006 Levetiracetam nationallicence difficult to treat epilepsy nationallicence side effects nationallicence open-label study nationallicence multicenter study nationallicence Levetiracetam nationallicence Schwer behandelbare Epilepsien nationallicence Nebenwirkungen nationallicence Offene Studie nationallicence Multizentrische Studie nationallicence Stefan H. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut Wang-Tilz Y. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut Feichtinger M. Neurologische Universitätsklinik, Graz, Österreich aut Kerling F. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut Mamoli B. Ludwig Bolzmann Institut für Epilepsie, Österreich aut Schaumann R. Schweizer Epilepsiezentrum, Zürich, Schweiz aut Krämer G. Schweizer Epilepsiezentrum, Zürich, Schweiz aut Zeitschrift für Epileptologie Steinkopff-Verlag 19/1(2006-02-01), 24-27 1617-6782 19:1<24 2006 19 10309 https://doi.org/10.1007/s10309-006-0184-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10309-006-0184-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Stefan H. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut NATIONALLICENCE 700 1- Wang-Tilz Y. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut NATIONALLICENCE 700 1- Feichtinger M. Neurologische Universitätsklinik, Graz, Österreich aut NATIONALLICENCE 700 1- Kerling F. Epilepsiezentrum Erlangen (ZEE), Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen, Germany aut NATIONALLICENCE 700 1- Mamoli B. Ludwig Bolzmann Institut für Epilepsie, Österreich aut NATIONALLICENCE 700 1- Schaumann R. Schweizer Epilepsiezentrum, Zürich, Schweiz aut NATIONALLICENCE 700 1- Krämer G. Schweizer Epilepsiezentrum, Zürich, Schweiz aut NATIONALLICENCE 773 0- Zeitschrift für Epileptologie Steinkopff-Verlag 19/1(2006-02-01), 24-27 1617-6782 19:1<24 2006 19 10309 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer